Correctiion to "Development of aortic valve disease in familial hypercholesterolemic swine: Implications for elucidating disease etiology" [J Am Heart Assoc. 2015;4:e002254]. doi: 10.1161/JAHA.115.002254;Development of aortic valve disease in familial hypercholesterolemic swine: Implications for elucidating disease etiology

Journal of the American Heart Association

Volumn 4, Issue 10, 2015, Pages

  Porras, Ana M ^a   Shanmuganayagam, Dhanansayan ^a   Meudt, Jennifer J ^a   Krueger, Christian G ^a   Hacker, Timothy A ^a   Rahko, Peter S ^a   Reed, Jess D ^a   Masters, Kristyn S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Aortic valve; Cardiovascular diseases; Hypercholesterolemia

Indexed keywords

COLLAGEN; ELASTIN; PROTEOGLYCAN; BIOLOGICAL MARKER; CHOLESTEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AORTA VALVE DISEASE; ARTICLE; ATHEROSCLEROSIS; CALCIFIC AORTIC VALVE DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; JUVENILE ANIMAL; LIPID OXIDATION; MACROPHAGE; MEMBRANE LEAFLET; NONHUMAN; PATHOGENESIS; PIG; PRIORITY JOURNAL; UPREGULATION; AGE; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD; CALCINOSIS; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART VALVE DISEASES; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR;

AGE FACTORS; ANIMALS; AORTIC VALVE; BIOMARKERS; CALCINOSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; HEART VALVE DISEASES; HYPERLIPOPROTEINEMIA TYPE II; MACROPHAGES; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC; SWINE; TIME FACTORS;

EID: 84991520024     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002007     Document Type: Erratum

References (64)

1. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157.
2. Civeira F; International Panel on Management of Familial H. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173:55-68.
3. Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol. 2014;7:107-117.
4. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus P. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478-3490a.
5. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation. 1987;76:504-507.
6. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-268.
7. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168:1-14.
8. Kawaguchi A, Miyatake K, Yutani C, Beppu S, Tsushima M, Yamamura T, Yamamoto A. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Am Heart J. 1999;137:410-418.
9. Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aorticvalve disease. N Engl J Med. 2003;349:717-718.
10. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783-1791.
11. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996;16:523-532.
12. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 1999;19:1218-1222.
13. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630-634.
14. Loomba RS, Arora R. Statin therapy and aortic stenosis: a systematic review of the effects of statin therapy on aortic stenosis. Am J Ther. 2010;17:e110-e114.
15. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
16. Liebe V, Brueckmann M, Borggrefe M, Kaden JJ. Statin therapy of calcific aortic stenosis: hype or hope? Eur Heart J. 2006;27:773-778.
17. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AP, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA. Statin treatment in children with familial hypercholesterolemia the younger, the better. Circulation. 2007;116:664-668.
18. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
19. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res. 2006;47:1339-1351.
20. Kang S, Wu Y, Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis. 2004;177:433-442.
21. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM III, Thomas JD, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Creager MA, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Stevenson WG, Yancy CW. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014;148:e1-e132.
22. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
23. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
24. Hasler-Rapacz J, Ellegren H, Fridolfsson AK, Kirkpatrick B, Kirk S, Andersson L, Rapacz J. Identification of a mutation in the low density lipoprotein receptor gene associated with recessive familial hypercholesterolemia in swine. Am J Med Genet. 1998;76:379-386.
25. Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:1104-1115.
26. Schinkel AF, Krueger CG, Tellez A, Granada JF, Reed JD, Hall A, Zang W, Owens C, Kaluza GL, Staub D, Coll B, Ten Cate FJ, Feinstein SB. Contrast-enhanced ultrasound for imaging vasa vasorum: comparison with histopathology in a swine model of atherosclerosis. Eur J Echocardiogr. 2010;11:659-664.
27. Tellez A, Krueger CG, Seifert P, Winsor-Hines D, Piedrahita C, Cheng Y, Milewski K, Aboodi MS, Yi G, McGregor JC, Crenshaw T, Reed JD, Huibregtse B, Kaluza GL, Granada JF. Coronary bare metal stent implantation in homozygous LDL receptor deficient swine induces a neointimal formation pattern similar to humans. Atherosclerosis. 2010;213:518-524.
28. Swinkels DW, Demacker PN. Comparative studies on the low density lipoprotein subfractions from pig and man. Comp Biochem Physiol B. 1988;90:297-300.
29. Balaoing LR, Post AD, Liu H, Minn KT, Grande-Allen KJ. Age-related changes in aortic valve hemostatic protein regulation. Arterioscler Thromb Vasc Biol. 2014;34:72-80.
30. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291-299.
31. Porras AM, Shanmuganayagam D, Meudt JJ, Krueger CG, Reed JD, Masters KS. Gene expression profiling of valvular interstitial cells in Rapacz familial hypercholesterolemic swine. Genom Data. 2014;2:261-263.
32. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
33. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
35. Latif N, Sarathchandra P, Taylor PM, Antoniw J, Yacoub MH. Localization and pattern of expression of extracellular matrix components in human heart valves. J Heart Valve Dis. 2005;14:218-227.
36. Imes CC, Austin MA. Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs. 2013;15:292-308.
37. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med. 2000;28:1685-1696.
38. Bosse Y, Miqdad A, Fournier D, Pepin A, Pibarot P, Mathieu P. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet. 2009;2:489-498.
39. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart. 1998;80:583-590.
40. Sider KL, Zhu C, Kwong AV, Mirzaei Z, de Lange CF, Simmons CA. Evaluation of a porcine model of early aortic valve sclerosis. Cardiovasc Pathol. 2014;23:289-297.
41. Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008;102:1438-1443.
42. Hamamdzic D, Wilensky RL. Porcine models of accelerated coronary atherosclerosis: role of diabetes mellitus and hypercholesterolemia. J Diabetes Res. 2013;2013:761415.
43. Rosenhek R, Klaar U, Schemper M, Scholten C, Heger M, Gabriel H, Binder T, Maurer G, Baumgartner H. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J. 2004;25:199-205.
44. Volzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, Rettig R, John U, Felix SB, Dorr M. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis. 2010;209:606-610.
45. Cosmi JE, Kort S, Tunick PA, Rosenzweig BP, Freedberg RS, Katz ES, Applebaum RM, Kronzon I. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med. 2002;162:2345-2347.
46. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
47. Kuusisto J, Rasanen K, Sarkioja T, Alarakkola E, Kosma VM. Atherosclerosislike lesions of the aortic valve are common in adults of all ages: a necropsy study. Heart. 2005;91:576-582.
48. Hinton RB Jr, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res. 2006;98:1431-1438.
49. Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res. 2011;108:1510-1524.
50. Rossebo AB, Pedersen TR. Hyperlipidaemia and aortic valve disease. Curr Opin Lipidol. 2004;15:447-451.
51. Rajamannan NM. Low-density lipoprotein and aortic stenosis. Heart. 2008;94:1111-1112.
52. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart. 2008;94:1175-1180.
53. Waller BF, Howard J, Fess S. Pathology of aortic valve stenosis and pure aortic regurgitation: a clinical morphologic assessment-Part II. Clin Cardiol. 1994;17:150-156.
54. Lars W, Thora S, Mats B. Role of inflammation in nonrheumatic, regurgitant heart valve disease. A comparative, descriptive study regarding apolipoproteins and inflammatory cells in nonrheumatic heart valve disease. Cardiovasc Pathol. 2007;16:171-178.
55. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211-1217.
56. Sider KL, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. Int J Inflam. 2011;2011:364310.
57. Cheek JD, Wirrig EE, Alfieri CM, James JF, Yutzey KE. Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol. 2012;52:689-700.
58. Fang M, Alfieri CM, Hulin A, Conway SJ, Yutzey KE. Loss of beta-catenin promotes chondrogenic differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol. 2014;34:2601-2608.
59. Mazzone A, Venneri L, Berti S. Aortic valve stenosis and coronary artery disease: pathophysiological and clinical links. J Cardiovasc Med (Hagerstown). 2007;8:983-989.
60. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316-3326.
61. Bahls M, Bidwell CA, Hu J, Tellez A, Kaluza GL, Granada JF, Krueger CG, Reed JD, Laughlin MH, Van Alstine WG, Newcomer SC. Gene expression differences during the heterogeneous progression of peripheral atherosclerosis in familial hypercholesterolemic swine. BMC Genom. 2013;14:443.
62. Crick SJ, Sheppard MN, Ho SY, Gebstein L, Anderson RH. Anatomy of the pig heart: comparisons with normal human cardiac structure. J Anat. 1998;193:105-119.
63. Kerut EK, Valina CM, Luka T, Pinkernell K, Delafontaine P, Alt EU. Technique and imaging for transthoracic echocardiography of the laboratory pig. Echocardiography. 2004;21:439-442.
64. McCoy CM, Nicholas DQ, Masters KS. Sex-related differences in gene expression by porcine aortic valvular interstitial cells. PLoS One. 2012;7: e39980.